Nabeela Ameer

Dr. Nabeela Ameer

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
NANabeela Ameer
Nabeela Ameer
MHMuhammad Hanif
Muhammad Hanif
GAGhulam Abbas
Ghulam Abbas
MMMuhammad Muhammad
Muhammad Muhammad
KMKhalid Mahmood
Khalid Mahmood
Baher DaihomBaher Daihom
Baher Daihom
Background: The lack of local availability for drugs in the colon can be addressed by preparing a self-microemulsifying drug delivery system (SMEDDS) of curcumin (Cur) which is ultimately used for the treatment of inflammatory bowel disease (IBD). Methods: From preformulation studies, Lauroglycol FCC (oil), Tween 80 (surfactant), Transcutol HP (co-surfactant), and Avicel (solid carrier) were selected for the preparation of blank liquid and solid Cur-loaded SMEDDSs (S-Cur-SMEDDSs). Results: Z-average size (12.36 ± 0.04 nm), zeta potential (−14.7 ± 0.08 mV), and polydispersity index (PDI) (0.155 ± 0.036) showed a comparative droplet surface area and charge of both SMEDDSs. The physicochemical stability of Cur in S-Cur-SMEDDSs was confirmed via FTIR, DSC, TGA, and XRD analyses, while morphological analysis through SEM and atomic force microscopy (AFM) confirmed Cur loading into SMEDDSs with an increased surface roughness root mean square (RMS) of 11.433 ± 0.91 nm, greater than the blank SMEDDS. Acute toxicity studies with an organ weight ratio and % hemolysis of 15.65 ± 1.32% at a high concentration of 600 mM showed that S-Cur-SMEDDSs are safe at a medium dose (0.2–0.8 g/kg/day). The excellent in vitro antioxidant (68.54 ± 1.42%) and anti-inflammatory properties (56.47 ± 1.17%) of S-Cur-SMEDDS proved its therapeutic efficacy for IBD. Finally, S-Cur-SMEDDS significantly improved acetic acid-induced IBD in albino rats through a reduction in the disease activity index (DAI) and macroscopic ulcer score (MUS) from 4.15 ± 0.21 to 1.62 ± 0.12 at 15 mg/kg/day dose, as confirmed via histopathological assay. Conclusions: Based on the above findings, S-Cur-SMEDDS appears to be a stable, less toxic, and more efficacious alternative for Cur delivery with strong competence in treating IBD.

1 January 2025 in Anais da Academia Brasileira de Ciências
Verified
Journal Article
Open access
PDF file
SUSyeda Aleena Ubaid
Syeda Aleena Ubaid
HAHafiz Muhammad Usman Abid
Hafiz Muhammad Usman Abid
MHMuhammad Hanif
Muhammad Hanif
KMKhalid Mahmood
Khalid Mahmood
MQMemoona Qayyum
Memoona Qayyum
NANabeela Ameer
Nabeela Ameer
Visceral bleeding poses a significant threat, requiring effective management through positively charged chitosan. This study aimed to address the limitations of chitosan-based hemostatic hydrogels by synthesizing a modified maleic anhydride complex of chitosan (MAC). Biocompatibility, biodegradability, and non-toxicity made MAC a suitable candidate for super porous hydrogels (SPHs) used in hemostatic applications. Graft polymerization synthesized MAC, confirmed via Fourier transform infrared spectroscopy, demonstrating superior antioxidant activity compared to chitosan and maleic anhydride. SPHs were prepared using MAC alone and with N, N-methylene bisacrylamide (MBA) as crosslinkers. MAC exhibited higher water absorbency and pH-dependent swelling than the MBA-chitosan complex. Drug loading and entrapment efficiency varied with the drug-to-SPH ratio. In vitro drug release studies showed sustained release (SR) with SPHs-MAC following zero-order kinetics and SPHs-MBA following Korsmeyer-Peppas. SPHs-MAC gelled more rapidly with temperature changes, and MAC hydrogels showed larger antimicrobial zones of inhibition (28±2).In vivo hemostasis studies revealed rapid hemostatic effects with MACL-H, reducing blood loss to 78.5 ± 1.5 mg in iver rat models. MAC hydrogels significantly lowered blood loss in rat tail amputation models compared to controls. This formulation demonstrates strong potential for effective visceral bleeding management.